Back to Ovarian Cancer
NCT02265861
NCT02265861
Who may be able to join
"Who might be able to join this trial:
- You are a woman who has been identified as having Polycystic Ovary Syndrome (PCOS), diagnosed using specific criteria that look at three features: higher-than-normal male hormone levels, irregular or absent ovulation, and a particular appearance of the ovaries on ultrasound (confirm with trial site)
- You may be placed into one of four groups based on which combination of these three features applies to you
Who may not be able to join:
- You are 35 years of age or older
- You have been found to have any other hormone-related conditions, such as thyroid or adrenal gland disorders
- You have taken any hormone-based medications or treatments within the last 3 months before joining the study
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Early Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Early Phase 1
Sponsor
Nanjing University School of Medicine
Registry
clinicaltrials_gov
Start date
1 January 2010
Est. completion
1 June 2012
Primary endpoints
Levels of vascular endothelial growth factor(VEGF) and angiotensin-Ⅱ(AT-Ⅱ)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.